中药治疗对台湾遗传性溶血性贫血患者总体、糖尿病相关及心血管疾病相关死亡率风险的影响
本研究利用台湾全国人群数据库,匹配9222对非中药与中药使用者,探讨中药对遗传性溶血性贫血患者死亡风险的影响。Cox模型显示,中药使用者总体死亡率(aHR 0.67,95%CI 0.61-0.73,p<0.001)、糖尿病相关死亡率(aHR 0.57,95%CI 0.40-0.82,p<0.001)和心血管疾病相关死亡率(aHR 0.59,95%CI 0.49-0.72,p<0.001)均显著降低。研究还通过关联规则和网络分析呈现了常用中药组合。
要点
- 中药使用与遗传性溶血性贫血患者总体死亡率降低相关(aHR 0.67)。
- 中药使用与糖尿病相关死亡率降低相关(aHR 0.57)。
- 中药使用与心血管疾病相关死亡率降低相关(aHR 0.59)。
核心结论
- 中药使用与遗传性溶血性贫血患者总体、糖尿病相关及心血管疾病相关死亡率风险降低显著相关。
研究设计与样本
- 基于台湾全国人群数据库的回顾性队列研究,共识别33278例遗传性溶血性贫血患者,匹配后纳入9222对非中药与中药使用者。
主要发现
- 中药使用者总体死亡率aHR为0.67(95%CI 0.61-0.73,p<0.001)。
- 中药使用者糖尿病相关死亡率aHR为0.57(95%CI 0.40-0.82,p<0.001)。
- 中药使用者心血管疾病相关死亡率aHR为0.59(95%CI 0.49-0.72,p<0.001)。
- 研究识别出两个常用中药组合:组合1含贝母、甘草、海螵蛸、桔梗、鱼腥草及辛夷清肺汤;组合2含当归与黄芪。
临床怎么用
- 对于遗传性溶血性贫血患者,可考虑在辨证基础上参考本研究中的中药组合(如含贝母、甘草等的组合或当归、黄芪组合)进行辅助治疗。
局限性
- 当前为回顾性研究,可能存在潜在偏倚,尚需随机临床试验评估上述中药产品的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary Hemolytic Anemias (HHAs) are a rare but heterogeneous group of erythrocytic diseases, characterized by intrinsic cellular defects due to inherited genetic mutations. We investigated the efficacy of Chinese herbal medicine (CHM) in reducing the overall, diabetes-related, and cardiovascular diseases (CVDs)-related mortalities among patients with HHAs using a nationwide population database. In total, we identified 33,278 patients with HHAs and included 9,222 non-CHM and 9,222 CHM matched pairs after matching. The Cox proportional hazards model was used to compare the risk of mortality between non-CHM and CHM users. The Kaplan-Meier method and log-rank test were used to compare the cumulative incidence mortality between non-CHM and CHM users. The CHM prescription patterns were presented by the association rules and network analyses, respectively. The CHM prescription patterns were presented by the association rules and network analyses, respectively. CHM users showed significant reduced risks for of overall (adjusted hazard ratio [aHR]: 0.67, 95% confidence interval [CI]: 0.61-0.73, p < 0.001), diabetes-related (aHR: 0.57, 95% CI: 0.40-0.82, p < 0.001), and CVDs-related (aHR: 0.59, 95% CI: 0.49-0.72, p < 0.001) mortalities compared with non-CHM users. Two CHM clusters are frequently used to treat Taiwanese patients with HHAs. Cluster 1 is composed of six CHMs: Bei-Mu (BM; Fritillaria cirrhosa D.Don), Gan-Cao (GC; Glycyrrhiza uralensis Fisch.), Hai-Piao-Xiao (HPX; Endoconcha Sepiae), Jie-Geng (JG; Platycodon grandiflorus (Jacq.) A.DC.), Yu-Xing-Cao (YXC; Houttuynia cordata Thunb.), and Xin-Yi-Qing-Fei-Tang (XYQFT). Cluster 2 is composed of two CHMs, Dang-Gui (DG; Angelica sinensis (Oliv.) Diels) and Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge). Further randomized clinical trials are essential to evaluate the safety and effectiveness of above CHM products and to eliminate potential biases in the current retrospective study.
引用
- Chiu ML, Chiou JS, Chen CJ, et al. Effect of Chinese Herbal Medicine Therapy on Risks of Overall, Diabetes-Related, and Cardiovascular Diseases-Related Mortalities in Taiwanese Patients With Hereditary Hemolytic Anemias. Front Pharmacol. 2022. PMID: 35712707. doi:10.3389/fphar.2022.891729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。